In adults, cirrhotic cardiomyopathy (CCM) has a significant incidence and impact on liver transplantation. For pediatric liver transplantation (pLT), data on liver-induced cardiac changes are scarce, and in particular, the comparison between cirrhotic and noncirrhotic liver disease has not been investigated. We retrospectively evaluated cardiac changes associated with CCM by echocardiography and 12-lead electrocardiogram in 198 pLT-candidates (median age 4.1 years) 4.2 before and 12 months after pLT. Results were correlated with the stage of liver fibrosis and cholestasis before transplantation. The left ventricular end-diastolic diameter (LVIDd) z score, left ventricular mass z score, and left ventricular mass index were significantly higher in cirrhotic patients (-0.10 versus 0.98, P < 0.001; -1.55 versus -0.42, P 5 0.001; 78.99 versus 125.64 g/m 2 , P 5 0.001, respectively) compared with children with noncirrhotic liver disease. Pathological z scores (>2SDS) for the LVIDd occurred more frequently in cirrhotic patients compared with patients with noncirrhotic liver disease (31/169 versus 1/29; P 5 0.03) and were significantly associated with cholestasis. All observed cardiac changes were reversible 1 year after pLT. Pathological LVIDd z scores correlated highly with intensive care unit (ICU) stay (9.6 days versus 17.1 days, respectively, P 5 0.002) but not with patient survival pre-LT or post-LT. In contrast to other studies, prolonged QTc time was not associated with liver cirrhosis in our patients. In conclusion, CCM-associated cardiac changes in pLT candidates with cirrhotic liver disease are frequent, mild, and associated with cholestasis and reversible after pLT. They may impact peritransplant care and posttransplant hospitalization time. Further prospective evaluation is warranted. In particular, for QTc time prolongation etiological factors, possible protective effects of ursodeoxycholic acid treatment and the use as a screening parameter for CCM should be verified.
impaired cofunction between the liver and heart has more recently gained attention and was first described in 2000.
(1) CCM in adults is defined by systolic and/or diastolic dysfunction, left ventricular hypertrophy, and/ or QTc interval prolongation. (2) The underlying mechanism of diastolic dysfunction in cirrhosis is likely due to the increased myocardial wall stiffness caused by myocardial hypertrophy, fibrosis, and subendothelial edema, which subsequently results in high filling pressures of the left ventricle and atrium. Recent findings suggest that bile acids (cholestasis) play a key role in the development of CCM. (3, 4) Several studies described cardiac abnormalities using echocardiography and electrocardiogram (ECG) examinations of cirrhotic patients. Raevens et al. (5) found a CCM incidence of 43% in 173 adult liver transplant candidates but could not detect any impact on outcome, and further studies (6, 7) could not identify an effect of diastolic dysfunction on survival. Few studies demonstrated a significantly elevated mortality in patients with CCM after liver transplantation (LT). (8) Abbreviations: aF, advanced fibrosis; AILD, autoimmune liver disease; ALF, acute liver failure; ALT, alamine aminotransferase; ARPKD, autosomal recessive polycystic kidney disease; AST, aspartate aminotransferase; BMI, body mass index; CCM, cirrhotic cardiomyopathy; ECG, electrocardiogram; FS, fibrosis score; GALD, gestational alloimmune liver disease; GGT, gamma-glutamyl transferase; IVSd, interventricular septum; ICU, intensive care unit; LBMD, liver-based metabolic disease; LT, liver transplantation; LVIDd, left ventricular enddiastolic diameter; LVM, left ventricular mass; LVMI, left ventricular mass index; LVPWTd, left ventricular posterior wall thickness; naF, nonadvanced fibrosis; PFIC, progressive familial intrahepatic cholestasis; pLT, pediatric liver transplantation; POT1, point of time 1; POT2, point of time 2; re-LT, re-liver transplantation.
A study by Bal et al. (9) showed a prolongation of the QTc interval ( > 440 milliseconds) in up to 50% of patients with cirrhosis of the liver and an association with sudden cardiac death. Only a few preliminary studies involving children are available. A very recent study by Fattouh et al. (10) claimed the need for more pediatric studies in the field of CCM with the aim to generate a more accurate description of this entity in pediatric patients and a pediatric-specific diagnostic plan. CCM has not been prospectively evaluated in children, and only limited observational reports on the incidence of CCM are available. There are no studies comparing echocardiography in patients with or without cirrhosis using established standardized z scores.
We aimed to evaluate the incidence of cardiac changes typically associated with CCM in children who were liver transplanted in our center between 2002 and 2013 (n 5 282), to compare cardiac changes in cirrhotic and noncirrhotic liver transplant patients before and after pediatric liver transplantation (pLT) and to correlate cholestasis and cardiac changes. We further aimed to interpret these findings in context with the healthy population's z scores. (11, 12) Additionally, we planned to correlate cardiac changes pretransplantation with the clinical outcomes in the perioperative period and the longterm outcomes after transplantation. We used similar echocardiographic values to determine cardiac changes such as those Desai et al. (13) used in 1 of the most important pediatric studies in this field so far, but we were able to include significantly more patients. These echocardiographic values are available in a large retrospective cohort, and they were analyzed in 2002 in the same way as they are today. The measurement is robust and avoids mistakes such as pseudonormalization in E/A evaluation. Other studies showed that diastolic dysfunction is mainly a result of left ventricular hypertrophy; (14, 15) therefore, analyses of left ventricular mass (LVM) z score, left ventricular end-diastolic diameter (LVIDd) z score, and left ventricular mass index (LVMI) were good surrogate parameters for diastolic dysfunction.
Patients and Methods
This is an observational single-center (Hannover Medical School, Hannover, Germany) cohort study investigating consecutive liver transplants in children between 2002 and 2013 with a median observation time of 16.2 months after transplantation. Cardiac assessments included an echocardiogram and 12-lead ECG performed on 2 occasions, namely, a pretransplant assessment before pLT, routinely performed as part of the evaluation for liver transplantation (median 4.2 months) and another assessment after pLT (median 12 months). Data were collected retrospectively between 2013 and 2014. This summary of the study was structured in accordance with the STROBE guidelines. (16) Exclusion criteria were preexisting primary cardiac disease, Alagille syndrome patients, patients with metabolic disease potentially leading to cardiomyopathy such as glycogen storage disease, patients in need of retransplantation within the first posttransplant year not caused by initial transplant failure, patients with incomplete data, and patients with singular primary portal thrombosis. Laboratory, ultrasound, ECG, and echocardiographic data have been analyzed from medical records between 2013 and 2014. The staging of the histopathology of liver cirrhosis in the explanted livers was assessed by a senior liver pathologist using the ISHAK fibrosis score. (17) Patients were classified as either having advanced liver fibrosis (ISHAK fibrosis score [FS] 4-6) or nonadvanced liver fibrosis (FS 0-3) in the explanted livers. Echocardiography and ECG results in pLT candidates were compared between the 2 groups. Clinical data, echocardiography results, ECG results, and laboratory results of the cohort were retrieved from (electronic) medical records.
The QTc interval was determined in a resting 12-lead EEG (Cardio Soft GE V6.73 GE Healthcare, Solingen, Germany) by a cardiologist. The QT measurements were performed in lead II for 3 consecutive beats. QT intervals were measured from the onset of the QRS complex to the end of the T wave. When U waves were present, the end of the T wave was taken at the nadir between the T and U waves. The Bazett formula was used for the heart rate correction (QTc). In accordance with the current guidelines, a QTc interval >440 ms was defined as prolonged.
For pre-LT analysis, echocardiography data were collected only from the examinations at our center. For post-LT analysis, also standardized echocardiography data of external examinations were accepted, if the data were sufficient. Echocardiography examinations at our center were performed by experienced pediatric echocardiography experts according to a standardized procedure.
To assess the structure and functional status of the heart, 2D, M-Mode, and Doppler echocardiography were performed by the standard technique of using the apical 4-chamber view and the left parasternal longand short-axis views (Philipps IE 33, Amsterdam, Netherlands, with a 12Hz, 8Hz, or 5Hz transducer, depending on age). The dimensions of the ventricles were measured at end-diastole and end-systole, all from M-Mode traces. The following parameters were measured: left ventricular end-diastolic diameter (LVIDd), left ventricular posterior wall thickness (LVPWTd), interventricular septum (IVSd), and left atrial diameter. The mitral Doppler signals were recorded in the apical 4-chamber view with the Doppler sample volume placed at the tip of the mitral valve leaflets. Furthermore, the E/A ratio was evaluated. The E/A ratio is the relationship between the peak velocity flow of the rapid early diastole passive filling of the left ventricle (the E wave) to peak velocity flow in late diastole filling caused by atrial contraction (the A wave).
The IVSd, LVIDd, and LVPWTd z scores were classified according to Kampmann, (11) and the LVM z score was classified according to Foster. (12) The LVM index was calculated based on the Devereux formula.
Outcomes were measured using the survival rate during the first transplant year, duration of the hospital stay, and duration of the intensive care unit (ICU) stay.
The study follow-up period was until 1-year checkup after pLT. Due to the retrospective nature of the study, an institutional review was not necessary. Patients gave consent about using data for research purposes and also gave consent for pLT.
Statistical analysis was performed using SPSS 24 and the Spearman-Rho correlation, Mann-Whitney U test, Kruskal Wallis test, and chi-square test.
Results
Out of 282 patients, 198 patients (97 females) fulfilled the inclusion criteria ( Fig. 1 ). The median age at LT was 4.14 years (SD 5.46; 0.2-18 years). At the pre-LT evaluation, we included 169 patients with advanced fibrosis (81 females) and 29 patients with nonadvanced fibrosis (16 females). Due to the death of 8 patients and insufficient echocardiographic data for evaluation 1 year after pLT, 132 patients (62 females) with advanced fibrosis and 15 patients (9 females) with nonadvanced fibrosis were included in the 1-year postpLT analyses (Fig. 1) . The median observation time was 18 months (mean 21.3 months; SD 11; 5-60).
In Table 1 , baseline characteristics of the patients including the underlying liver disease are displayed. The advanced fibrosis and the nonadvanced fibrosis groups were significantly different in age at pLT, diseases, liver fibrosis, and also for the interval from the pre-pLT echocardiography to the pLT, with a longer time for patients with advanced fibrosis. There were no significant differences for quick, albumin, ALT, AST, and body mass index (BMI) as well as the z score for BMI; however, we found significantly higher values in patients with advanced fibrosis for bilirubin, serum bile acids, gamma-glutamyltransferase (GGT), and spleen length. We found no significant differences regarding the amount of ascites (evaluated by ultrasound) or blood electrolytes between the 2 groups.
CARDIAC CHANGES PRE-PLT IN ASSOCIATION TO FIBROSIS
At the pre-pLT evaluation, we found significantly higher values for LVIDd z scores, LVM z scores, and for the LVMI in patients with advanced fibrosis compared with patients with nonadvanced fibrosis ( Fig.  2A ,B and Table 2 ).
Although the average z score for the advanced fibrosis group is not pathological (<2), this group had significantly (P 5 0.03) more patients with a pathological , respectively; P 5 0.001. Detailed analysis specific for aldosterone treatment even showed no significant association at all. The same picture was observed for the association of ascites and CCM. There was a significant association only for the LVMI z score and the amount of ascites; that is, a higher LVMI z score corresponded to a higher amount of ascites (P 5 0.04).
The spleen size at the time of the echocardiograph examination (in cm over 2SD of height-dependent percentiles of spleen length) correlated significantly (P 5 0.005; r 5 0.206) with the LVM z score.
QTc time was not significantly different between patients with advanced fibrosis and patients with nonadvanced fibrosis at LT (Table 2) 
REVERSIBILITY OF CARDIAC CHANGES POST-PLT
At the clinical review of the 1-year post-pLT evaluation, all the above mentioned cardiac changes had resolved themselves. Therefore, the comparison of the pre-pLT LVIDd z scores, LVM z scores, and the LVMI to post-pLT values showed significant differences (Fig. 3A,B) . The LVIDd z scores pre-pLT had a mean of 0. Of 132 patients, 11 (8.3%) did not return to normal z scores (below 2) 1 year after transplantation, 3 of these in more than 1 parameter. Due to small numbers, statistical analysis is crucial, but 4 of these 11 patients needed or are listed for retransplantation; that is a retransplantation rate of 36.4% in contrast to a retransplantation rate of 18.2% in our overall pediatric liver transplantation statistics (787 liver transplantations in 644 patients). Of these 4 patients, 3 have had transplant-cirrhosis due to biliary complications and 1 due to chronic rejection. Of the 11 patients, 1 died in the posttransplant period due to multiorgan failure.
OUTCOME AND CARDIAC CHANGES
Outcome analyses with respect to duration of hospital stay showed significant results only for the LVIDd z scores. Patients with a pathological LVIDd z score (>2) had significantly longer durations of ICU stay than patients with nonpathological LVIDd z scores, 17.5 (8.5-26.6) versus 9.5 (8.1-10.8), respectively; P 5 0.003 (Fig. 4) . Even after reducing possible confounders and the diversity of patients' baseline characteristics by analyzing only the group with advanced fibrosis, the duration of the ICU stay was still significantly longer for patients with a LVIDd z score above 2, 17.9 (8.5-27.3) versus 9.6 (8.1-11.1), respectively; P 5 0.005. The duration of the general hospital stay tended to be longer in patients with pathological LVIDd z scores compared with patients with nonpathological LVIDd z scores; 56.9 (45.9-67.9) versus 42.8 (36.5-49.1), respectively; P 5 0.05.
A total of 8 patients from our cohort died during the hospital stay for pLT: 7 patients from the group with advanced fibrosis and 1 patient from the group with nonadvanced fibrosis. Nevertheless, survival was neither statistically significantly associated with advanced fibrosis nor with cardiac findings.
CHOLESTASIS AND CARDIAC CHANGES
Bilirubin blood levels correlated significantly with the LVMI (r 5 0.413, P < 0.001) and LVIDd z score prepLT (r 5 0.203, p 5 0.004). For subcohort analyses of only biliary atresia patients (n 5 100), the correlation was even stronger (LVMI r 5 0.5, P < 0.001; LVIDd z score r 5 0.258, P 5 0.01; LVM z score r 5 0.228, P 5 0.025). A similar picture could be found in analyses of bile acids even though not all patients (n 5 147) in this analysis could be included due to missing data. The serum bile acid levels correlated significantly with the LVMI (r 5 0.487, P < 0.001), LVIDd z score prepLT (r 5 0.193, P 5 0.02), and LVM z score (r 5 0.178, P 5 0.03). Patients with pathological LVIDd z scores showed significantly higher mean values in serum bile acid levels (195. 15 
Discussion
In this, the largest study cohort investigating cardiac changes associated with CCM in childhood liver disease published to date, we were able to describe mild but significant cardiac changes in pLT candidates with advanced liver fibrosis. We could also demonstrate an association of these findings with the ICU stay and patient's serum bilirubin and bile acid levels; therefore, we showed for the first time that results of in vitro studies on association of bile acids and cardiac changes can be transferred to in vivo results in a pLT-cohort. Our study used z scores for echocardiographic values, which allowed comparison independent of age and body composition and interpretation of the results in the context of normal distribution of healthy children. Ours was also the first study to compare pLT candidates with liver-histology proven advanced versus nonadvanced fibrosis pre-pLT and post-pLT for aspects of CCM. This is an eminent advantage since the histology of an explanted liver is the most reliable evaluation of fibrosis stage and we could evaluate a control group of patients with liver disease and liver transplantation with proven absence of advanced liver fibrosis and correlate the cardiac changes to a reliable evaluated fibrosis stage. Most studies published so far only used indirect models to describe cirrhosis such as Pediatric End-Stage Liver Disease/ Model for End-Stage Liver Disease (PELD/ MELD) or Child-Pugh score.
In our study, we excluded patients with chronic, noncirrhotic portal hypertension due to primary portal vein thrombosis. Including them into the main cohort could produce a bias, as up to now it is unclear if CCM is mainly driven by portal hypertension, as in hepatopulmonary syndrome, or by liver cirrhosis and our aim was to evaluate the association of cardiac changes to severity of liver fibrosis. Of course it would be of great interest to compare a group of noncirrhotic portal hypertension patients with a group of cirrhotic hypertension patients, similar to the study by Celtik et al. (18) where they could not find any patients with CCM in the noncirrhotic portal hypertension group (n 5 10). However, we were not able to include enough patients with noncirrhotic portal hypertension to run this type of analysis.
CARDIAC CHANGES PRE-PLT IN ASSOCIATION WITH FIBROSIS
Our results demonstrated clearly that advanced liver fibrosis is associated with cardiac changes. Although they were subtle, they were detectable via echocardiography by comparing pLT candidates with advanced fibrosis with pLT candidates with nonadvanced fibrosis ( Fig. 2A,B) . Furthermore, we demonstrated that the pathological results for the LVIDd z score are significantly more frequent in pLT candidates with advanced fibrosis than in pLT candidates with nonadvanced fibrosis.
Our study groups (patients with nonadvanced fibrosis and patients with advanced fibrosis) differed significantly in age at pLT and during the interval from the pre-pLT evaluation to the performance of the pLT ( Table 1 ). The younger age of patients with advanced fibrosis was associated with the natural course of biliary atresia as the most frequent diagnosis in this group, but since we used z scores for comparisons, this did not affect our results. The shorter interval from the pre-pLT evaluation to the performance of the pLT in patients with nonadvanced fibrosis can be explained by the higher number of high urgency transplantations in this group due to patients with ALF, malignancies, and urea cycle disorders. We believe that this factor did not influence our results. One could argue that a longer interval could conceal the development of CCM, but this would even strengthen our results, since the group with longer intervals was the group with more pathological cardiac findings. The following aspects make it unlikely that our echocardiographic findings were caused mainly by fluid overload. We could not find a significant difference in the amount of ascites between patients with advanced fibrosis and patients with nonadvanced fibrosis. Serum sodium levels are decreased in patients with end-stage liver disease due to fluid overload. In our study, serum sodium levels were not different in the 2 groups and were only poorly correlated with the LVMI and LVIDd (r 5 0.292 and P < 0.001, respectively; r 5 0.145 and P 5 0.000, respectively) but not with the LVM z score (P 5 0.99). Except for the LVMI, our results were independent of the status of diuretic medication in patients with advanced fibrosis. Our results for cardiac changes under liver fibrosis are in accordance with results from Desai et al., (3) but their study only compared patients with biliary atresia (n 5 40) with healthy controls (n 5 40); therefore, they could not test for the association of the stage of fibrosis with cardiac changes. Similarly, the recent study from Fattouh et al. (10) described increased LVPWTd in 53 patients with liver cirrhosis compared with healthy controls. Arikan et al. (19) found significantly higher values only for the LVPWTd and left atrium diameter in pLT candidates with chronic liver disease compared with healthy controls; however, no association to disease severity was observed. The study was performed without evaluation of the histological stage of fibrosis and without using z scores; therefore, a reliable comparison of patients with different severity of disease was not possible.
Surprisingly, we could not find a significant difference in QTc time between patients with advanced fibrosis and patients with nonadvanced fibrosis at liver transplantation. We tested for bias due to different sodium, potassium, calcium, and magnesium serum levels in the 2 groups, but as shown in Table 1 , these parameters were equal for both groups. However, our results can be explained by significant association of QTc intervals with disease since the mean value of QTc interval was longest in our ALF patients and all patients with pathological QTc intervals from the nonadvanced fibrosis group (n 5 3) were patients with ALF. This again could possibly be explained by prophylactic fluconazole therapy in these patients as well as by a higher incidence of hepatic encephalopathy (HE) in patients with ALF and the fact that QTc prolongation can be driven by HE. (20) Furthermore, Bal et al. (9) and Zhao et al. (21) showed that a prolonged QTc interval in adult liver transplant candidates was associated with older age and alcoholic liver cirrhosis. In their study of pediatric liver transplant candidates, Arikan et al. (19) showed that patients had significantly longer QTc intervals in comparison to healthy controls; however, the mean QTc was still not in a pathological range. Therefore, it is not possible to argue from this study that prolonged QTc is associated with the stage of fibrosis. Indeed, other studies (22) also showed that the QTc prolongation does not correlate with severity of liver cirrhosis or portal hypertension. It seems that other factors may contribute to the QTc time prolongation. Vasavan et al. (23) described elevated bile acids as a factor and ursodeoxycholic acid as a reliable treatment (prophylactic and therapeutic). This is in line with the fact that we found significantly higher levels of serum-bilirubin in our patients with pathological (>450 ms) QTc intervals. That we could not find this association for bile acids may be founded on a bias due to ursodeoxycholic acid treatment. Since this treatment could be prophylactic, (23) it would be of interest to know if patients in studies with high amounts of pathological QTc and cirrhosis were also treated with ursodeoxycholic acid as in our study. In summary, it has to be taken into account that a prolonged QTc interval could be a phenomenon that is associated with liver disease but not directly related to the stage of liver fibrosis.
In Table 2 , we included data of the E/A ratio. We could not find any association with stage of fibrosis for this parameter but the way the parameter was measured and the parameter itself is not very reliable in our cohort because ratio is very preload-dependent; with a high heart rate (young children) show a fusion of E and A; interpretation of E/A ratios the deceleration time is important, which wasn't documented for most of our patients; and moderate diastolic dysfunction, E/ A shows a pseudonormalization which can only be detected with tissue Doppler technique (E/E ratio) and was not available for most patients due to the retrospective manner of the study.
REVERSIBILITY OF CARDIAC CHANGES POST-PLT
Although it is commonly assumed that CCM resolves after LT, we still believe it is important to show our post-LT data, which show a complete vanishing of significant differences between patients with advanced and nonadvanced fibrosis 1 year after pLT. Therefore, we observed significant differences between pre-pLT and post-pLT values in the advanced fibrosis group (Fig. 3A,B) . These data also serve as a control marker for our methods and underline that cardiac changes in our patients were not influenced by any cause or disease other than liver fibrosis. Additionally, it was important to underline the effect of improving cardiac changes after LT versus studies that showed the opposite. (24) Furthermore, the data implicate the opportunity of outcome analyses in these patients.
The fact that in 11 of 132 patients (8.3%), who have nonresolved cardiac changes after pLT, the retransplantation rate is considerably higher (36.4%) than in our overall statistic, and that most of these patients have been retransplanted due to biliary cirrhosis, leads to the question of whether (persisting) cirrhotic-induced cardiac change could lead to impaired perfusion of the transplanted liver after pLT causing damage to the sensible biliary tracts. In our data, this is still speculative and has to be confirmed in prospective multicenter studies.
OUTCOME AND CARDIAC CHANGES
The only 2 studies in the pediatric field that correlated post-pLT outcomes to cardiac changes associated with CCM are from Desai in 2011 (13) and from Jang in 2016. (25) Both studies showed longer hospital and ICU stays for patients with abnormal cardiac findings. This is in accordance with our results. Although the duration of the ICU stay was dependent on numerous factors, we found significantly longer ICU stays for patients with pathological LVIDd z scores (>2). We could not observe a significant association between cardiac findings and survival during the peri-pLT period. We also could not observe a significant association of survival to advanced fibrosis.
CHOLESTASIS AND CARDIAC CHANGES
We found a significant correlation between bilirubin and serum bile acids to the LVMI, LVM z score, and LVIDd z score. Further, we could show that patients with a pathological LVIDd z score have significantly higher levels of serum-bilirubin and serum-bile acids. This confirms the first findings from recent animal studies where bile acids have been found to be an initiator of CCM. (3, 4) We used total bilirubin alongside serum bile acids as a surrogate parameter for cholestasis since the serum levels of bile acids could be biased by ursodeoxycholic acid treatment, which is used in most of our patients with chronic liver disease. Nevertheless, the results are similar for both parameters.
LIMITATIONS
We are aware of the limitations of this study, especially in the outcome analyses. Many different factors play a role in the duration of hospital and ICU stays (open abdomen, timing of second look, timing of bile duct anastomosis, age of patient, type of liver graft). However, we are confident that our results deliver important information and can serve as a basis for further prospective studies.
Another potential confounder could be the mix of diseases in our cohort since disease-specific factors could play a role for development of CCM; therefore, a cohort with 1 disease would be ideal, but then a comparison of different fibrosis scores would be difficult. Patients would need to receive planned liver biopsies in an early stage of the disease and multiple follow-up biopsies to compare different fibrosis stages.
Since our study cohort starts with pLTs from 2002, we could not imply the newest echocardiographic methods such as tissue Doppler and strain analysis, which could detect even more subtle changes. Left ventricular mass by calculation using the Devereux formula is not the gold standard for LVM and LVMI evaluation. Currently, the gold standard is cardiac MRI, but this is not applicable in this cohort, and most studies are based on the calculation approach. Additionally, our study compared the LVM z score and LVMI between our patient groups; therefore, a possible error would not play a crucial role.
We are aware that malnutrition can also cause cardiomyopathy, and this is difficult to exclude. All endstage liver disease patients are malnourished; however, we showed that BMI was not different between the 2 groups, and with the knowledge that the amount of ascites is not significantly different between the groups, BMI can be used as a marker for malnutrition.
Conclusion
In conclusion, we could demonstrate cardiac changes, detectable by echocardiography, in pLT candidates with advanced liver fibrosis, associated with cholestasis and in most patients reversible after liver transplantation without impact on survival, but we could observe a significant prolonged ICU stay after pLT for patients with cardiac changes pre-pLT. Furthermore, the high retransplantation rate of 36.4% in the 11 patients (8.3%) with persistent cardiac changes leads to the assumption that persistent cardiac changes may influence organ survival and, in particular, lead to biliary tract problems. Our results regarding QTc time prolongation in liver cirrhosis show that the QTc time must be evaluated separately and cannot be used as a single screening parameter for cirrhotic-induced cardiac changes. The QTc time seems to be influenced by further parameters and could be influenced by consequent ursodeoxycholic acid treatment. Based on our results, future prospective studies can be developed, which are necessary to characterize CCM and the impact on outcome in pLT candidates. Until then patients with liver cirrhosis and especially patients with biliary cirrhosis should be regularly screened for cardiac changes by echocardiography and ECG pre-pLT, peri-LT, and post-pLT. Patients with biliary cirrhosis should be treated consistently with ursodeoxycholic acid.
